TY - JOUR
T1 - Radiation plus adjuvant CCNU (1-[2-chloroethyl]-3cyclohexyl-1-nitrosourea) vs CCNU, hydroxyurea and vincristine in the treatment of malignant glimoa
AU - Costanza, Mary
AU - Buechler, Mary
AU - Munzenreider, John
AU - Emami, Bahman
AU - Mukherji, Bijay
AU - Shucart, William
AU - Scott, Michael
AU - Nathanson, Larry
AU - Rudders, Richard
AU - Stein, Bennett
AU - Post, Kalmon
AU - Piro, Anthony
PY - 1979/9
Y1 - 1979/9
N2 - Following maximal surgery, 25 patients with malignant glioma were randomized to receive either radiation therapy and CCNU or radiation therapy and CCNU, hydroxyurea, and vincristine. Radiation therapy included 4000 rad to whole brain followed by 1500 rad to the primary. Chemotherapy was either: CCNU alone 130 mg/m2 PO every 6 weeks or triple drug chemotherapy given in 6 week cycles of CCNIJ go mg/m2 PO (one dose), vincristine 1 mg/m2 IV (one dose), and hydroxyurea 1.5 gm/m2 PO every 3 days × 7 doses. Thirteen patients received CCNU alone. Of these, 8 are dead, 2 are alive with progressive disease and 3 are alive with stable disease at 10, 22 and 23 months. Median survival is 10 months. Twelve patients received CCNU, vincristine and hydroxyurea. Of these, 8 are dead, 1 is alive with progressive disease and 3 are stable. Median survival is 9.5 months +. Toxicity included nausea, which was common, leukopenia < 3000 in 7 patients and thrombocytopenia in 9 patients. There were no episodes of bleeding or infection attributable to chemotherapy. Although toxicity was tolerable, no additional benefit could be demonstrated for triple agent chemotherapy with CCNU, vincristine and hydroxyurea compared to CCNU alone. Median survival for both groups was similar at 42-44 weeks.
AB - Following maximal surgery, 25 patients with malignant glioma were randomized to receive either radiation therapy and CCNU or radiation therapy and CCNU, hydroxyurea, and vincristine. Radiation therapy included 4000 rad to whole brain followed by 1500 rad to the primary. Chemotherapy was either: CCNU alone 130 mg/m2 PO every 6 weeks or triple drug chemotherapy given in 6 week cycles of CCNIJ go mg/m2 PO (one dose), vincristine 1 mg/m2 IV (one dose), and hydroxyurea 1.5 gm/m2 PO every 3 days × 7 doses. Thirteen patients received CCNU alone. Of these, 8 are dead, 2 are alive with progressive disease and 3 are alive with stable disease at 10, 22 and 23 months. Median survival is 10 months. Twelve patients received CCNU, vincristine and hydroxyurea. Of these, 8 are dead, 1 is alive with progressive disease and 3 are stable. Median survival is 9.5 months +. Toxicity included nausea, which was common, leukopenia < 3000 in 7 patients and thrombocytopenia in 9 patients. There were no episodes of bleeding or infection attributable to chemotherapy. Although toxicity was tolerable, no additional benefit could be demonstrated for triple agent chemotherapy with CCNU, vincristine and hydroxyurea compared to CCNU alone. Median survival for both groups was similar at 42-44 weeks.
KW - CCNU
KW - Glioma
KW - Hydroxyurea
KW - Radiation therapy
KW - Vincristine
UR - http://www.scopus.com/inward/record.url?scp=0018604794&partnerID=8YFLogxK
U2 - 10.1016/0360-3016(79)90778-8
DO - 10.1016/0360-3016(79)90778-8
M3 - Article
C2 - 231595
AN - SCOPUS:0018604794
SN - 0360-3016
VL - 5
SP - 1589
EP - 1592
JO - International Journal of Radiation Oncology Biology Physics
JF - International Journal of Radiation Oncology Biology Physics
IS - 9
ER -